February 04, 2016
Astellas Pharma agreed Thursday to pay indirect purchasers of its Prograf $13.25 million to settle claims that it delayed generic competition to the immunosuppressant drug amid an appeal of class certification in the antitrust case.
May 21, 2015
A Massachusetts federal judge on Wednesday signed off on a $98 million deal between buyers of organ transplant anti-rejection drug Prograf and Astellas Pharma US Inc., ending allegations Astellas delayed entry of a generic form of the immunosuppressant, while also approving a request from the buyers' lawyers for $34 million in fees and expenses.
April 10, 2015
Attorneys for certain buyers of organ transplant anti-rejection drug Prograf sought $34 million in fees and expenses Thursday, three months after reaching a $98 million deal with Astellas Pharma US Inc. over allegations it delayed entry of a generic form of the immunosuppressant.
March 06, 2015
The First Circuit will hear Astellas Pharma US LLC's appeal of a judge's decision to partially certify a class of consumers and companies in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, according to court filings.
January 22, 2015
Astellas Pharma US LLC will pay $98 million to resolve some of the suits in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, according to a Thursday filing in Massachusetts federal court.
January 20, 2015
Astellas Pharma US LLC said on Tuesday that it had agreed in principle to a deal that would resolve some of the suits in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, just as a trial was set to start in Massachusetts federal court.
June 19, 2013
Covington & Burling LLP said Tuesday that certain evidence requested in Massachusetts federal court by a class of direct purchasers is not relevant to multidistrict antitrust litigation accusing Astellas Pharma US Inc. of delaying entry of a generic version of the immunosuppressant Prograf.
June 04, 2013
A direct purchaser class on Tuesday pushed a Massachusetts federal court to force Covington & Burling LLP to produce evidence that could be relevant to multidistrict antitrust litigation accusing Astellas Pharma US Inc. of delaying entry of a generic form of its immunosuppressant Prograf.
April 24, 2013
A Massachusetts federal judge on Tuesday certified a class of pharmaceutical companies in multidistrict antitrust litigation that accuses Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market, forcing the plaintiffs to pay higher prices for the drug.
February 01, 2012
A Massachusetts federal judge on Wednesday refused to dismiss multidistrict antitrust litigation accusing Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market and forcing direct purchasers to pay higher prices for the drug.